Keyword: Keytruda

As a big ESMO 2018 kicks off, here are the studies we're most excited to see.

On Thursday, Merck’s Keytruda hit the scene with kidney cancer combination data that could snag it a new use months earlier than anticipated.

A policy change by the board of Merck & Co. will allow Ken Frazier to remain CEO after he turns 65 next year.

Merck halves Keytruda's price in China; Takeda eyes selling Shire's Xiidra and Natpara; another ex-GSK scientist pleads guilty to trade secret theft.

Merck & Co. has priced Keytruda at about $2,600 per vial in China, about a 50% discount compared to its U.S. tag.

Here is some other vaccine news of note for the week.

The U.K. cost watchdog says it doesn't have the PD-1's overall survival data to assess its cost-effectiveness.

Roche has been chomping at the bit to challenge Merck in previously untreated lung cancer, but it’s going to have to wait a little longer.

England's cost watchdog has decided Merck’s blockbuster Keytruda is not a good treatment choice in Hodgkin lymphoma—at least not for all patients.

Merck is getting ready to take on Pfizer and Merck KGaA’s Bavencio in a rare form of skin cancer, and the FDA just sped up the showdown.